Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen : Morgan Stanley Adjusts Price Target on Amgen to $280 From $278, Maintains Overweight Rating

07/16/2021 | 11:10am EDT


ę MT Newswires 2021
All news about AMGEN INC.
09/24AMGEN : FDA Approves Repatha« (evolocumab) In Pediatric Patients Age 10 And Older With Het..
PR
09/24FDA APPROVES AMGEN'S REPATHA AS ADD- : Bloomberg
MT
09/23WALL STREET STOCK EXCHANGE : As smooth as silk
09/23AMGEN : Daiwa Securities Downgrades Amgen to Neutral From Outperform, Price Target at $220
MT
09/23ANALYST RECOMMENDATIONS : Amgen, Apple, AstraZeneca, FedEx, T-Mobile US...
09/22AMGEN : To Present At The 2021 Cantor Global Healthcare Conference
PR
09/22AMGEN : Releases 8th Edition of Biosimilar Trends Report
PR
09/22AMGEN : Investor Presentation September 2021
PU
09/21AMGEN : Margaret Chu-Moyer Honored with Prestigious Portoghese Lectureship
PU
09/21AMGEN : Secures Favorable Ruling in Patent Dispute Against Sandoz, Zydus Over Psoriasis Dr..
MT
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 046 M - -
Net income 2021 6 027 M - -
Net Debt 2021 22 255 M - -
P/E ratio 2021 21,1x
Yield 2021 3,24%
Capitalization 121 B 121 B -
EV / Sales 2021 5,51x
EV / Sales 2022 5,18x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 213,61 $
Average target price 243,90 $
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-7.09%121 299
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037